# **Special Issue**

# Chronic Inflammatory Skin Diseases: From Bench to Bedside

# Message from the Guest Editor

Chronic inflammatory skin diseases represent the largest class of chronic skin conditions, being a major issue not only in dermatology but also in general medicine. This Special Issue is dedicated to discussing the latest research, developments and new ideas from bench to bedside. We would like to offer new perspectives regarding diagnosis, clinical manifestations and therapeutic approach to chronic inflammatory skin diseases such as psoriasis. hidradenitis suppurativa, atopic dermatitis, autoimmune bullous and non-bullous diseases. Despite undisputed achievements over the last few decades, we still do not fully understand all of these diseases. The complexity of the immunological background, the clinical heterogeneity and the presence of several comorbidities, including metabolic syndrome, cardiovascular diseases and others, make our everyday clinical practice a challenge. We look forward to receiving your best original research and review papers.

#### **Guest Editor**

Dr. Alexandra Maria Giovanna Brunasso Villa Scassi Hospital, Genoa, Italy

### Deadline for manuscript submissions

closed (16 May 2023)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/127848

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





# **About the Journal**

# Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

## Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).